Estimating the long-term health impact of nicotine exposure by dissecting the effects of

nicotine versus non-nicotine constituents of tobacco smoke:

A multivariable Mendelian randomisation study

Khouja, J. N.[1,2*], Sanderson, E.[2,3], Wootton, R.E.[1,2,6], Taylor, A. E.[2,3], Church, B. A.[5],

Richmond, R. C.[2,3] & Munafo, M. R.[1,2,4]

[1] School of Psychological Science, University of Bristol, Bristol, United Kingdom, BS8 1TU

[2] Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK,

BS8 2BN

[3] Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK, BS8

2BN

[4] NIHR Bristol Biomedical Research Centre, Bristol, UK, BS8 2BN

[5] School of Psychology and Vision Sciences, University of Leicester, UK, LE1 7HA

[6] Nic Waals Institute, Lovisenberg diakonale sykehus, Oslo, Norway, 0456

*Corresponding author

Email: jasmine.khouja@bristol.ac.uk

17
Short title: Health effects of nicotine versus non-nicotine constituents of tobacco smoke

Abstract

The detrimental health effects of smoking are well-known, but the impact of long-term

nicotine use without exposure to the other constituents of tobacco is less clear. Given the

increasing long-term use of alternative nicotine delivery systems, such as e-cigarettes, it is

increasingly important to understand and separate the effects of long-term nicotine use

from the impact of tobacco smoke exposure. Using a multivariable Mendelian

randomisation framework, we explored the direct effects of nicotine compared with the

non-nicotine constituents of tobacco smoke on health outcomes (lung cancer, chronic

obstructive pulmonary disease [COPD], forced expiratory volume in one second [FEV-1],

forced vital capacity [FVC], coronary heart disease [CHD], and heart rate [HR]). The results

suggest that these smoking-related outcomes are not due to nicotine exposure but are

caused by the other components of tobacco smoke; however, there are multiple potential

sources of bias, and the results should be triangulated using evidence from a range of

methodologies.

Although the detrimental health effects of smoking are well known [1], it is less clear which

individual components of cigarette smoke – such as nicotine – drive these effects. In recent

years, it has become increasingly important to fill this knowledge gap, given the increase in

the popularity of alternative nicotine delivery systems, in particular e-cigarettes [2]. E-

cigarettes are often used by smokers to stop smoking and are generally used for longer

periods than conventional cessation aids which also contain nicotine (e.g., nicotine patches)

[3, 4]. Although *short-term* use of nicotine without the remaining constituents of tobacco

smoke is relatively harmless, the *long-term* harms of nicotine use are poorly understood [5].

Given many smokers choose to use e-cigarettes to reduce their risk of poor health outcomes

[2], and that e-cigarettes can be used with or without nicotine, smokers and e-cigarette

users need causal evidence regarding the possible health outcomes related to long-term

nicotine use to make informed decisions regarding their e-cigarette use.

Randomised controlled trials (RCT) are often employed to explore causal relationships [6],

but an RCT would be unethical and impractical in this scenario – non-smokers would need to

be unnecessarily exposed to nicotine for decades to understand the (potentially harmful)

long-term effects of nicotine use without confounding from exposure to cigarette smoke.

Mendelian randomisation (MR) is an alternative method which can be used in scenarios

where RCTs are implausible or unethical. MR uses genetic variants associated with the

exposure of interest to serve as instrumental variables to estimate the effect of that

exposure on a particular outcome [7, 8]. Nonetheless, they require well powered genome-

wide association studies (GWAS) to identify such genetic variants. There are currently no

available GWAS of e-cigarette use or nicotine exposure without exposure to tobacco.

Furthermore, there are insufficient data available to conduct a well-powered GWAS. Novel

methods are therefore required to explore this research question.

Multivariable MR (MVMR) is an extension of MR that can be used to explore the direct

effect of one exposure on an outcome while accounting for the effect of another

(potentially correlated) exposure or exposures [9]. The method is robust to pleiotropic

effects of the single nucleotide polymorphisms (SNPs) used as instruments through the

other exposures included in the model. As large-scale GWAS have identified SNPs that are

associated with smoking heaviness [10] (i.e., the number of cigarettes a person smokes per

day) and the nicotine metabolite ratio (i.e., how quickly a person metabolises nicotine – see

below) [11] among smokers, we can employ this method to explore the effect of nicotine on

selected health outcomes. Rather than exploring the total effect of smoking on a health

outcome (which includes the effect of nicotine), this method allows us to separate the direct

effect of nicotine versus the other constituents of tobacco smoke.

However, direct measurement of nicotine is difficult. Metabolites of nicotine such as

cotinine (a direct metabolite) and 3'hydroxycotinine (3HC; a metabolite of cotinine) are

often used as objective measures to proxy for nicotine given the short half-life of nicotine

itself [12] (Supplementary Figure S1). Cotinine and cotinine plus 3HC are highly specific

biomarkers, but both are impacted by metabolism (which can differ between individuals).

The nicotine metabolite ratio (NMR), is a measure of how quickly a person metabolises

nicotine (3'hydroxycotinine/cotinine) and therefore causally impacts the amount of nicotine

in a person's body given a set amount of nicotine exposure [13]. Figure 1 illustrates that a

smoker with a higher NMR (Person A) will have less circulating nicotine in their body than a

smoker with a lower NMR (Person B) given the same level of nicotine exposure; however,

because smokers with a higher NMR clear nicotine quickly from their system, this often

results in them smoking more cigarettes per day (CPD) [14]. In a standard MR model with

NMR as an exposure, the result may be ambiguous as it could reflect the effect of higher

nicotine exposure resulting from increased smoking heaviness or lower nicotine exposure

resulting from faster metabolism. In contrast, when both NMR and CPD are included in an

MVMR model (Figure 2), the analysis is analogous to a fixed access experiment in which the

amount of smoke exposure / cigarettes smoked is fixed and the effect of nicotine exposure

per cigarette smoked can be assessed. Therefore, in an MVMR framework accounting for

genetic predisposition to CPD, the results should dissect the direct effect of nicotine levels

per cigarette smoked from the direct effect of the other constituents of tobacco smoke,

whereby an increase in NMR reflects lower exposure to nicotine (Figure 1).

Figure 1. Illustration of the impact of the nicotine metabolite ratio on circulating nicotine

and smoking heaviness.

Note: This illustration shows the differences in nicotine exposure between two people who

smoke: Person A who has a high nicotine metabolite ratio, and Person B who has a low

nicotine metabolite ratio. At timepoint 1 (T1) both Person A and B smoke one cigarette and

inhale the same amount of nicotine which can be seen circulating in their body at timepoint

2 (T2). Later, at timepoint 3 (T3), Person A will have less circulating nicotine in their body

than Person B (despite having inhaled the same level of nicotine) as more of the nicotine

has been metabolised into cotinine. However, because smokers with higher nicotine

metabolite ratios clear nicotine more quickly from their system, this often results in them

smoking more cigarettes per day. So, at timepoint 4 (T4), Person A smokes another cigarette

whereas Person B does not. This results in Person A having more circulating nicotine than

Person B over the same time period [14].

Figure 2. Schematic of the study model

Note: This schematic shows the proposed causal pathways of the study model. Where the causal directions between variables are known

(i.e., evidenced in previous research), the direction of the effect is indicated as 'positive' or 'negative'. NMR = Nicotine Metabolite Ratio. G =

genetic variants associated with the named exposure.

Using this framework, it is possible to explore the effects of nicotine and the effects of the

remaining constituents of tobacco smoke on health outcomes known to be impacted by

smoking, and which therefore may be impacted by long-term nicotine use, such as cancer

and heart and lung function [15-17]. We employed a two-sample MVMR framework to

explore the direct effects of nicotine compared with the non-nicotine constituents of

tobacco smoke on health outcomes (lung cancer, chronic obstructive pulmonary disease

[COPD], forced expiratory volume in one second [FEV-1], forced vital capacity [FVC],

coronary heart disease [CHD] and heart rate [HR]). These outcomes include positive and

negative control outcomes to aid causal inference; nicotine use is known to increase heart

rate, but is not thought to be carcinogenic, so if the results do not provide evidence of an

effect of nicotine on heart rate, and / or if they suggest an effect of nicotine on lung cancer,

the results may indicate bias from a violation of the assumptions of MR [18-20]. In

supplemental analyses, our secondary aim is to compare the results with analyses using

alternative proxies for nicotine exposure (i.e., cotinine and cotinine plus 3HC).

133   **Methods**

Data Sources

To identify relevant instrumental variables to include in the model, we sourced summary-

level genetic data from well-powered, published GWAS. We identified SNPs associated with

NMR, cotinine, cotinine plus 3HC and smoking heaviness (measured by CPD) [10, 11, 21].

For the outcomes, we required data to be stratified by smoking status in order to be

comparable with the population of the exposure GWAS data. An appropriately stratified

GWAS (stratified by smoking status: ever versus never [22]) was only available for one of the

outcomes, lung cancer. For the six remaining outcomes, we were not aware of any existing

available GWAS summary-level data that appropriately stratified by smoking status. We

therefore used UK Biobank data to conduct GWAS of CHD, COPD, FEV, FVC and HR, stratified

by smoking status and restricted to individuals of European ancestry. These analyses were:

1) stratified by whether participants had ever smoked, and further stratified into 2) current

smoker, or 3) former smoker, with 4) never smoker as the comparator, and were conducted

using the MRC Integrative Epidemiology Unit UK Biobank GWAS pipeline (version 2) [23, 24].

We also conducted stratified GWAS of body mass index (BMI) using UK Biobank data with

the intention of including BMI as an outcome. However, these methods and results are not

presented here as we identified a potential interpretation issue: the NMR GWAS was

adjusted for BMI, meaning these results would likely be biased [25].

Smoking heaviness

Liu and colleagues [10] report summary-level statistics from a GWAS meta-analysis of

smoking heaviness (measured by standard deviation change in CPD categories, equivalent to

2-3 additional cigarettes per day) among 337,334 smokers of European ancestry in the

GWAS and Sequencing Consortium of Alcohol and Nicotine (GSCAN). Smokers were defined

as having ever or currently smoked and smoking heaviness (at the time of smoking) was

binned into five categories or included as pre-defined bins from the original study (see

supplementary material in Liu and colleagues, [10]. Analyses were adjusted for age, age-

squared, sex, genetic principal components, and smoking status (current versus former).

SNPs associated with CPD explained 4% of variance in CPD. SNPs were reported as

independent if they explain additional variance in conditional analyses using a partial

correlation-based score statistic [26]. The reported data are available

at: https://doi.org/10.13020/3b1n-ff32.

Nicotine

Buchwald and colleagues [11] report summary-level statistics from a GWAS meta-analysis of

the standard deviation change in NMR among 5,185 current smokers of European descent

with cotinine levels ≥10 ng/ml (indicating recent smoking). NMR is a ratio of

3'hydroxycotinine/cotinine which indicates how quickly a person metabolises and clears

nicotine. Analyses were adjusted for population substructure, age, sex, BMI, alcohol use,

and birth year. The SNPs associated with NMR explained ~38% of the variance in NMR. SNPs

were reported as independent if they explained additional variance in a step-wise

conditional regression using genome-wide complex trait analysis [27]. The reported data are

available on request from the authors. Information relating to the nicotine measures used in

the supplemental analysis (using cotinine and cotinine plus 3HC data as a proxy for nicotine

exposure) can be found in the Supplementary Material (Supplemental Note S1).

Lung Cancer

McKay and colleagues [22] report summary-level statistics from a case-control GWAS meta-

analysis of overall lung cancer risk (including adenocarcinoma, squamous cell carcinoma,

and small cell carcinoma) among 50,046 individuals of European descent using the

International Lung Cancer Consortium (ILCCO). Analyses were adjusted for age, gender,

country (if applicable) and significant principal components. We received the data via

request to the authors and we additionally received the data stratified by smoking status

(ever versus never smoking). Definitions of ever and never smoking differed by cohort

included in the meta-GWAS. Details of the definitions can be found in McKay and

colleagues' [22] supplementary note.

Non-Cancer Smoking-Related Health Outcomes

We conducted GWAS of non-cancer health outcomes using data from UK Biobank, a

population-based health research resource consisting of approximately 500,000 people,

aged between 38 years and 73 years, who were recruited between the years 2006 and 2010

from across the UK [28]. UK Biobank has a particular focus on identifying determinants of

human diseases in middle-aged and older individuals who provided a wide range of health

information (data available at www.ukbiobank.ac.uk). A full description of the study design,

participants, and quality control (QC) methods have been described previously [28, 29]. UK

Biobank received ethics approval from the Research Ethics Committee (REC reference for UK

Biobank is 11/NW/0382). Written informed consent was obtained from participants prior to

their participation in UK Biobank. Approval to use these data was sought from and

approved by UK Biobank (project 9142). All studies approved by UK Biobank do not require

individual ethical clearance as UK Biobank has approval from the North West Multi-centre

Research Ethics Committee as a Research Tissue Bank under which each approved study

operates.

The full data release contains the cohort of successfully genotyped samples (n=488,377).

Further information about genotyping and imputation can be found in the Supplementary

Material (Supplemental Note S2). Individuals with mismatched sex were excluded and the

analyses were restricted to those of 'European' ancestry using an in-house k-cluster means

method. The GWAS were conducted using the linear mixed model (LMM) association

method as implemented in BOLT-LMM (v2.3) [30], adjusting for genotype array, age and sex

[23]. BOLT-LMM association statistics are on the linear scale, so test statistics (betas and

their corresponding standard errors) relating to binary phenotypes were transformed to log

odds ratios and their corresponding 95% confidence intervals (95% CI) on the liability scale

using a Taylor transformation expansion series [31]. Each outcome was stratified by self-

reported participant smoking status (ever [further stratified by current or former] and

never), resulting in four GWAS per outcome. Smoking status was categorised as never,

previous, and current smoking in UK Biobank (field ID 20116). From this variable, we derived

an 'ever smokers' category which was defined as currently or having previously smoked

occasionally, most days or daily (i.e., having smoked more than just once or twice). Current

smoking was defined as currently smoking occasionally, most days or daily. Former smoking

was defined as not currently smoking but having previously smoked occasionally, most days

or daily (i.e., more than just once or twice). Those who had tried smoking once or twice or

who had never smoked were categorised as never smokers.

We identified COPD cases as participants who self-reported a doctor's diagnosis of COPD.

Lung function (FEV-1 and FVC, in litres) was measured using a Vitalograph spirometer. CHD

diagnosis was determined using linked hospital admission data (ICD codes relating to

Ischemic Heart Disease). Further information regarding each health outcome (including UK

Biobank field IDs) can be found in the Supplementary Material (Supplemental Note S3).

Statistical Analysis

All analyses were conducted using R version 1.4.1.

Selection of genetic variants

We selected conditionally independent (at the genome-wide significant level, $p < 5 \times 10^{-8}$)

genetic variants identified in the GWAS of NMR and CPD for inclusion in the analysis [10,

11]; 55 SNPs associated with smoking heaviness were identified as conditionally

independent [10]; 7 SNPs associated with the NMR were identified as conditionally

independent.

After removing SNPs which were not available in the outcome GWAS (where no available

proxy could be identified), harmonising, and clumping the combined exposure datasets with

the outcome dataset, the number of SNPs in each analysis varied. Supplementary Tables S1-

S6 detail which SNPs were included and excluded (with reasons) in each analysis, and

Supplemental Note S4 gives further details of the proxy search and clumping methods.

We tested instrument strength and validity using the two-sample conditional F-statistic for

MVMR and Cochran Q statistic [9, 32]. The conditional F-statistic for MVMR indicates

instrument strength of each exposure when accounting for the prediction of other

exposures in the model (i.e., whether the SNPs jointly predict smoking heaviness after

predicting the NMR, and vice versa) [33]. The standard critical values for the F-statistic and

Q-statistic can be approximated so F-statistic should be greater than 10 to indicate sufficient

instrument strength and Q estimates should be less than the number of SNPs included in

the model to indicate no excessive heterogeneity [34, 35].

Univariable Mendelian randomisation

For comparison with the MVMR analysis, we considered the total effect of both the NMR

and smoking heaviness on each health outcome using MR. We used four complementary

MR methods (inverse variance weighted [MR-IVW], MR-Egger, weighted median, weighted

mode). Details of the univariable MR analysis methods can be found in Supplemental Note

S5.

Multivariable Mendelian randomisation

We explored the direct effects of both the NMR and smoking heaviness on health outcomes

using MVMR. We used summary data from Buchwald and colleagues' [11], GSCAN [10] and

ILCCO [22], and UK Biobank GWAS pipeline results. We repeated these analyses using two

complementary methods – MVMR-IVW and MVMR-Egger [9, 36].

Given that the GWAS of smoking heaviness was restricted to ever smokers and the GWAS of

the NMR was restricted to current smokers, the analyses were restricted to ever and

current smokers as the summary statistics are not applicable to never smokers. However,

the ILCCO lung cancer data have only been stratified by ever and never smoking status;

therefore, analyses restricted to current smokers were not possible when exploring lung

cancer incidence. In supplementary analyses, we additionally stratified the analysis by never

smokers to explore potential horizontal pleiotropy – effects observed among never smokers

could indicate horizontally pleiotropic effects (i.e., the included SNPs influencing the

outcome directly, or via another phenotype, but not through the measured exposure),

misreporting of smoking status, or residual population stratification. Horizontally pleiotropic

genetic variants are not valid instruments in MR analyses and their inclusion would result in

a violation of the exclusion restriction assumption (further details on the assumptions of MR

can be found in Supplemental Note S6). Pleiotropy robust methods (e.g., MR-Egger) are

robust to horizontal pleiotropy under assumptions of the form that pleiotropy takes. For all

outcomes except lung cancer (where data are unavailable), we also included supplementary

results restricted to former smokers to explore whether any health effects found among

current smokers may be recoverable (i.e., not present among former smokers who have

recovered following smoking cessation).

290   **Results**

Descriptive Statistics

Smoking heaviness data were collected from 337,334 current and former smokers who

reported their current or past smoking behaviour respectively (analyses corrected for

current versus former status, average bin 3 [SD = 1] equating to 16-25 cigarettes per day)

[10]. NMR data were collected from 5,185 current smokers [11]. Case rates and means (with

standard deviations) for the outcomes in each of the samples included in the analyses are

shown in Table 1.

Table 1. Descriptive statistics for participants included in the genome-wide association

studies of lung cancer, coronary heart disease, chronic obstructive pulmonary disease, lung

function and heart rate.

	Ever smokers	Current Smokers	Former Smokers	Never Smokers
International Lung Cancer Consortium				
N	40,187	N/A	N/A	9,859
Lung Cancer (case rate)	57%	N/A	N/A	24%
UK Biobank				
N	213,341	49,721	163,620	258,056
Coronary Heart Disease (case rate)	11%	11%	11%	6%
Chronic Obstructive Pulmonary Disease (case rate)	3%	6%	2%	<1%

Forced Expiratory Volume (mean litres [SD])	2.82 (0.78)	2.78 (0.83)	2.83 (0.76)	2.88 (0.78)
Forced Vital Capacity (mean litres [SD])	3.78 (0.97)	3.81 (1.02)	3.78 (0.96)	3.78 (0.99)
Heart Rate (mean beats per minute [SD])	69.05 (11.38)	71.27 (11.58)	68.40 (11.23)	68.93 (11.10)

Note: SD = standard deviation

Instrument strength and heterogeneity

Where the Cochran's Q statistic was greater than the number of SNPs included in the

model, it is advised to focus on pleiotropy robust methods as this indicates heterogeneity

and potential pleiotropy. MR-Egger and MVMR-Egger give estimates that are robust to

directional horizontal pleiotropy under the assumption that this pleiotropy is uncorrelated

with the strength of association between the SNP and the exposure [36]. However, using

the MR-Egger and MVMR-Egger methods limits the statistical power of the analysis

compared to MVMR-IVW. Therefore, although we present the IVW results in the text, we

have explicitly stated where the sensitivity analyses differ substantially (i.e., where the

results could lead to different conclusions) and in these cases, additionally compare the

Egger results (and weighted mode and weighted median results) in the MR analyses.

The F-statistics indicate that the SNPs included in these analyses are strong instruments for

assessing the direct effects of smoking heaviness while accounting for the effect of the NMR

(Fs = 33.96 and 34.17) and for assessing the direct effects of the NMR while accounting for

smoking heaviness (Fs = 30.17 and 49.08).

Binary outcomes

The total and direct effects of the NMR and smoking heaviness on lung cancer, CHD, COPD, and are shown in Figure 3 (ever smokers). These results are also included in Supplementary Tables S7 (lung cancer), S8 (CHD), and S9 (COPD) along with the F-statistics, Q-statistics and Egger intercept and the results among current, never and formers smokers. We have focussed on the results among ever smokers rather than current smokers here as receiving a diagnosis of lung cancer, CHD or COPD may increase the likelihood of someone quitting smoking, so the results are more relevant and interpretable among ever smokers. The results among current smokers can be found in Supplemental Note S7 and Supplementary Figure S2. Additionally, we have included the median and mode weighted MR sensitivity analyses in Supplementary Table S10. Results are presented as odds ratios per standard deviation (SD) increase in the exposure phenotype (i.e., per SD increase in the NMR or cigarettes per day).

Exposure	Health Outcome	Method	OR (95% CI)	P value
Nicotine Metabolite Ratio	CHD	MR-IVW	1.02 (0.99, 1.04)	0.199
		MVMR-IVW	1 (0.98, 1.03)	0.771
		MR-Egger	1.04 (0.99, 1.1)	0.191
		MVMR-Egger	1 (0.97, 1.03)	0.816
Smoking Heaviness	CHD	MR-IVW	1.14 (1.01, 1.29)	0.04
		MVMR-IVW	1.32 (1.08, 1.62)	0.011
		MR-Egger	0.95 (0.79, 1.14)	0.574
		MVMR-Egger	0.94 (0.68, 1.28)	0.686
Nicotine Metabolite Ratio	COPD	MR-IVW	1.16 (1.07, 1.24)	<0.001
		MVMR-IVW	1.03 (0.95, 1.12)	0.474
		MR-Egger	1.24 (1.06, 1.45)	0.051
		MVMR-Egger	1.04 (0.95, 1.14)	0.393
Smoking Heaviness	COPD	MR-IVW	6.57 (4.68, 9.2)	<0.001
		MVMR-IVW	7.24 (3.99, 13.15)	<0.001
		MR-Egger	4.92 (2.96, 8.18)	<0.001
		MVMR-Egger	4.44 (1.67, 11.79)	0.005
Nicotine Metabolite Ratio	Lung Cancer	MR-IVW	1.2 (1.15, 1.25)	<0.001
		MVMR-IVW	1.01 (0.94, 1.08)	0.866
		MR-Egger	1.31 (1.21, 1.42)	0.007
		MVMR-Egger	1 (0.92, 1.07)	0.926
Smoking Heaviness	Lung Cancer	MR-IVW	4 (3.5, 4.57)	<0.001
		MVMR-IVW	2.94 (2.38, 3.62)	<0.001
		MR-Egger	5.53 (4.73, 6.48)	<0.001
		MVMR-Egger	4.58 (3.45, 6.09)	<0.001

Figure 3. Forest plot displaying the effect of nicotine metabolite ratio and smoking heaviness on
coronary heart disease (CHD), chronic obstructive pulmonary disease (COPD) and lung cancer
incidence: univariable Mendelian randomisation (MR) and multivariable Mendelian randomisation
(MVMR) results among ever smokers.

Lung Cancer

The MR-IVW results indicate strong evidence to suggest that increased NMR and increased

smoking heaviness both increase the risk of developing lung cancer among ever smokers

(odds ratio [OR] = 1.20, 95% confidence interval [CI] 1.15 to 1.25; OR = 4.00, 95% CI 3.50 to

4.57 respectively). However, the MVMR-IVW results do not provide clear evidence to

suggest an effect of NMR on lung cancer risk (OR = 1.01, 95% CI 0.94 to 1.08), and indicate

that only increased smoking heaviness increased lung cancer risk (OR = 2.94, 95% CI 2.38 to

3.62). Although there is considerable evidence of heterogeneity and potential pleiotropy in

the smoking heaviness analyses among ever smokers, these results are supported by the

MR-Egger results. Furthermore, there is no clear evidence of pleiotropy or bias due to

population stratification indicated by the results among never smokers.

Coronary Heart Disease

The MR-IVW results provide no clear evidence that NMR affects CHD risk (OR = 1.02, 95% CI

0.99 to 1.04). This is supported by the MR-Egger results, but the weighted median and

weighted mode results suggested there may be a weak effect (OR = 1.03, 95% CI 1.01 to

1.05, OR = 1.03, 95% CI 1.01 to 1.05 respectively). The results provide some evidence that

increased smoking heaviness increases CHD risk (OR = 1.14, 95% CI 1.01 to 1.29) among ever

smokers. The weighted median and weighted mode results support this finding (OR = 1.14,

95% CI 1.02 to 1.29, OR = 1.14, 95% CI 1.02 to 1.27 respectively); however, the MR-Egger

analysis does not support this (OR = 0.95, 95% CI 0.79 to 1.14), and there is some evidence

of heterogeneity indicated by the Q-statistics and the Egger intercept indicated weak

directional pleiotropy which is supported by evidence of a protective effect among never

smokers. The MVMR-IVW results provide no clear evidence of an effect of NMR on CHD risk

(OR = 1.00, 95% CI 0.98 to 1.03) but some evidence that increased smoking heaviness

increases CHD risk (OR = 1.32, 95% CI 1.08 to 1.62). As with the univariable results, the

MVMR-Egger analyses do not support this (OR = 0.94, 95% CI 0.68 to 1.28) and there was

evidence of heterogeneity and potential directional pleiotropy and some evidence of

horizontal pleiotropy or bias due to population stratification in the analysis among never

smokers.

Chronic Obstructive Pulmonary Disease

The MR-IVW results indicate that increased NMR and smoking heaviness increase the risk of developing COPD among ever smokers (OR = 1.16, 95% CI 1.07 to 1.24, OR = 6.57, 95% CI 4.68 to 9.20 respectively). However, the MVMR-IVW results indicate no clear effect of NMR on COPD risk (OR = 1.03, 95% CI 0.95 to 1.12) but suggest that increased smoking heaviness increases COPD risk among ever smokers (OR = 7.24, 95% CI 3.99 to 13.15). These results are supported by the MR sensitivity analyses and MVMR-Egger results and there is no clear evidence of heterogeneity or directional pleiotropy or horizontal pleiotropy or bias due to population stratification among never smokers (where precise null effects were observed).

Continuous outcomes

The total and direct effects of the NMR and smoking heaviness on lung function (FEV-1 and FVC) and heart rate are shown in Figures 4 (ever smokers) and 5 (current smokers). These results are also displayed in Supplementary Tables S11 (FEV-1), S12 (FVC), and S13 (heart rate) along with the F-statistics, Q-statistics and Egger intercept and the results among ever, current, never and formers smokers. Additionally, we have included the median and mode weighted MR sensitivity analyses in Supplementary Table 10. Results are presented as betas per standard deviation (SD) increase in the exposure phenotype (i.e., per SD increase in the NMR or cigarettes per day). As per MR-STROBE guidelines [37], we have reported the results in text on an interpretable scale (i.e., difference in outcome in relevant units e.g., mL). However, to aid comparability across outcomes, we present the results per standard deviation change in the forest plots.

Exposure	Health Outcome	Method	B (95% CI)	P value
Nicotine Metabolite Ratio	FEV–1	MR–IVW	−0.02 (−0.02, −0.01)	<0.001
		MVMR–IVW	0 (−0.02, 0.01)	0.399
		MR–Egger	−0.03 (−0.04, −0.01)	0.013
		MVMR–Egger	0 (−0.01, 0.01)	0.653
Smoking Heaviness	FEV–1	MR–IVW	−0.24 (−0.28, −0.19)	<0.001
		MVMR–IVW	−0.23 (−0.31, −0.15)	<0.001
		MR–Egger	−0.25 (−0.32, −0.18)	<0.001
		MVMR–Egger	−0.23 (−0.36, −0.1)	0.001
Nicotine Metabolite Ratio	FVC	MR–IVW	−0.01 (−0.02, −0.01)	<0.001
		MVMR–IVW	−0.01 (−0.02, 0)	0.27
		MR–Egger	−0.02 (−0.03, −0.01)	0.009
		MVMR–Egger	−0.01 (−0.02, 0.01)	0.407
Smoking Heaviness	FVC	MR–IVW	−0.13 (−0.18, −0.09)	<0.001
		MVMR–IVW	−0.15 (−0.23, −0.07)	0.001
		MR–Egger	−0.1 (−0.17, −0.03)	0.008
		MVMR–Egger	−0.09 (−0.22, 0.04)	0.182
Nicotine Metabolite Ratio	HR	MR–IVW	0.01 (0, 0.01)	0.217
		MVMR–IVW	0 (−0.01, 0.01)	0.577
		MR–Egger	0 (−0.02, 0.02)	0.695
		MVMR–Egger	0 (−0.01, 0.01)	0.737
Smoking Heaviness	HR	MR–IVW	0.14 (0.1, 0.18)	<0.001
		MVMR–IVW	0.14 (0.06, 0.22)	0.001
		MR–Egger	0.11 (0.05, 0.18)	0.001
		MVMR–Egger	0.11 (−0.02, 0.24)	0.101

−0.4 0 0.3

Figure 4. Forest plot displaying the effect of nicotine metabolite ratio and smoking heaviness on standard deviations of lung function (FEV-1 and FVC), and heart rate (HR): univariable Mendelian randomisation (MR) and multivariable Mendelian randomisation (MVMR) results among ever smokers.

Exposure	Health Outcome	Method	B (95% CI)	P value
Nicotine Metabolite Ratio	FEV–1	MR–IVW	−0.04 (−0.05, −0.03)	<0.001
		MVMR–IVW	−0.02 (−0.04, −0.01)	0.006
		MR–Egger	−0.05 (−0.07, −0.02)	0.014
		MVMR–Egger	−0.02 (−0.03, 0)	0.017
Smoking Heaviness	FEV–1	MR–IVW	−0.45 (−0.51, −0.39)	<0.001
		MVMR–IVW	−0.33 (−0.43, −0.22)	<0.001
		MR–Egger	−0.56 (−0.65, −0.47)	<0.001
		MVMR–Egger	−0.43 (−0.6, −0.26)	<0.001
Nicotine Metabolite Ratio	FVC	MR–IVW	−0.02 (−0.03, −0.01)	<0.001
		MVMR–IVW	−0.01 (−0.03, 0)	0.063
		MR–Egger	−0.02 (−0.04, 0)	0.127
		MVMR–Egger	−0.01 (−0.03, 0)	0.119
Smoking Heaviness	FVC	MR–IVW	−0.24 (−0.3, −0.18)	<0.001
		MVMR–IVW	−0.19 (−0.29, −0.09)	<0.001
		MR–Egger	−0.26 (−0.35, −0.18)	<0.001
		MVMR–Egger	−0.19 (−0.35, −0.03)	0.025
Nicotine Metabolite Ratio	HR	MR–IVW	0 (−0.02, 0.01)	0.477
		MVMR–IVW	−0.03 (−0.04, −0.01)	0.006
		MR–Egger	−0.03 (−0.05, 0)	0.138
		MVMR–Egger	−0.03 (−0.05, −0.01)	0.005
Smoking Heaviness	HR	MR–IVW	0.4 (0.32, 0.48)	<0.001
		MVMR–IVW	0.36 (0.24, 0.49)	<0.001
		MR–Egger	0.38 (0.25, 0.5)	<0.001
		MVMR–Egger	0.29 (0.08, 0.49)	0.009

Figure 5. Forest plot displaying the effect of nicotine metabolite ratio and smoking
heaviness on standard deviations of lung function (FEV-1 and FVC), and heart rate (HR):
univariable Mendelian randomisation (MR) and multivariable Mendelian randomisation
(MVMR) results among current smokers.

Forced Expiratory Volume in 1 Second

The results relating to FEV-1 are presented in the text as changes in millilitres (mL) of

expiration per standard deviation increase in the exposure. The MR-IVW results indicate

that increased NMR and smoking heaviness both decrease FEV-1 among ever smokers

(Figure 4, b = -13.35, 95% CI -18.38 to -8.33, b = -185.49, 95% CI -220.39 to -150.60

respectively). However, there is no clear evidence of an effect of NMR on FEV-1 in the

MVMR-IVW analysis (b = 3.82, 95% CI -12.63 to 4.98), whereas there is evidence to suggest

increased smoking heaviness decreased FEV-1 among ever smokers (b = -176.78, 95% CI -

239.15 to -114.41). These results are supported by the MR sensitivity analyses and MVMR-

Egger results and there is no evidence of directional pleiotropy in the analyses, but there is

evidence of heterogeneity in all analyses except for the NMR MR analyses. However, there

is evidence of horizontal pleiotropy or bias due to population stratification in the NMR MR

analyses among never smokers.

Among current smokers (Figure 5), the MR-IVW results indicate that increased NMR and

smoking heaviness decreased FEV-1 (b = -33.33, 95% CI -41.76 to -24.90, b = -374.28, 95% CI

-428.21 to -320.35 respectively). However, the MVMR-IVW results indicate a protective

effect of nicotine exposure (i.e., lower nicotine exposure, due to higher NMR, lowers lung

function) when smoking heaviness is accounted for among current smokers (NMR b = -

17.77, 95% CI -29.92 to -5.62). The MVMR-IVW analyses support the MR-IVW results for

smoking heaviness (b = -272.36, 95% CI -359.31 to -185.42). These results are supported by

the MR sensitivity analyses and MVMR-Egger analyses. There is some evidence of

heterogeneity in all analyses except the NMR MR analyses, directional pleiotropy in the MR

analysis of smoking heaviness, and horizontal pleiotropy or bias due to population

stratification in the NMR MR analyses among never smokers.

Forced Vital Capacity

The results relating to FVC are presented in the text as changes in mL of capacity per

standard deviation increase in the exposure. The MR-IVW results indicate that increased

NMR and smoking heaviness decreased FVC among ever smokers (Figure 4, b = -14.34, 95%

CI -19.42 to -9.26, b = -129.63, 95% CI -174.27 to -85.00 respectively). However, there is no

clear evidence of an effect of NMR on FVC in the MVMR-IVW analysis (b = -6.32, 95% CI -

17.41 to 4.77), whereas there is evidence to suggest increased smoking heaviness decreased

FVC among ever smokers, after accounting for NMR (b = -149.55, 95% CI -228.07 to -71.03).

These results are supported by the MR sensitivity analyses and MVMR-Egger results,

although there is less clear evidence of an effect in the MVMR-Egger results for smoking

heaviness than in the MR-Egger results. There is some evidence of heterogeneity in all

analyses except the NMR MR analyses, but no clear evidence of directional pleiotropy.

There is weak evidence to suggest potential horizontal pleiotropy / bias due to population

stratification in the NMR MR analyses and the smoking heaviness MR-IVW analysis among

never smokers.

Among current smokers (Figure 5), the MR-IVW results suggest that increased NMR and

smoking heaviness decreased FVC (b = -24.50, 95% CI -34.61 to -14.39, b = -246.13, 95% CI -

304.36 to -187.89 respectively). MVMR-IVW results support the evidence for an effect of

smoking cessation on FVC but indicate weak evidence of a protective effect of nicotine

exposure when smoking heaviness is accounted for (NMR b = -13.50, 95% CI -27.39 to 0.39).

The MR median and mode weighted analyses support these findings, and the MR-Egger and

MVMR-Egger results are in the same direction but provide weaker support for the NMR

results. There is evidence in the MVMR-IVW analysis to suggest that increased smoking

heaviness decreases FVC (b -195.31, 95% CI -294.72 to -95.90), which is supported by the

MVMR-Egger results. There is some evidence of heterogeneity in all analyses except the

NMR MR analyses, but no clear evidence of directional pleiotropy. There is weak evidence

to suggest potential horizontal pleiotropy or bias due to population stratification in the NMR

MR analyses and the smoking heaviness MR-IVW analysis among never smokers.

Heart Rate

The results relating to heart rate are presented in the text as changes in beats per minute

per standard deviation increase in the exposure. Among ever smokers (Figure 4), the MR-

IVW results suggest that increased NMR does not affect heart rate (b = 0.06, 95% CI -0.04 to

0.16), but increased smoking heaviness does increase heart rate (b = 1.61, 95% CI 1.12 to

2.10). The MVMR-IVW results support the results for both NMR and smoking heaviness (b =

-0.04, 95% CI -0.16 to 0.09, b = 1.63, 95% CI 0.73 to 2.54 respectively). The MR sensitivity

analyses and MVMR-Egger results also support these findings. There is some evidence of

heterogeneity in all analyses, but no clear evidence of directional pleiotropy. There is weak

evidence to suggest potential horizontal pleiotropy or bias due to population stratification in

the MR-IVW NMR, MR-IVW and MR-Egger smoking heaviness analyses among never

smokers.

Among current smokers (Figure 5), the MR-IVW results indicate no clear effect of NMR on

heart rate (b = -0.05, 95% CI -0.20 to 0.09) but indicate that increased smoking heaviness

increases heart rate (b = 4.58, 95% CI 3.65 to 5.51). However, the MVMR-IVW results

suggest that decreased NMR when accounting for smoking heaviness (i.e., increased

nicotine exposure per cigarette) increases heart rate among current smokers (b = -0.30, 95%

CI -0.50 to -0.10) and increased smoking heaviness accounting for nicotine exposure

increases heart rate (b = 4.22, 95% CI 2.77 to 5.68). The MR sensitivity and MVMR-Egger

results support the MR-IVW and MVMR-IVW findings. There is some evidence of

heterogeneity in all analyses except the MR NMR analyses, but no clear evidence of

directional pleiotropy. There is weak evidence to suggest potential horizontal pleiotropy /

bias due to population stratification in the MR-IVW NMR, MR-IVW and MR-Egger smoking

heaviness analyses among never smokers.

Interpreting the NMR MVMR results

In the MVMR results above, we interpret an increase in the direct effect of NMR as a

reduction in nicotine exposure per cigarette smoked. Supplementary Table S14 illustrates

how the estimated direct effects of NMR found can be flipped to indicate the effect of

increased nicotine exposure per cigarette smoked on the outcome.

Sensitivity and supplementary analysis

The results of the sensitivity analyses whereby cotinine and cotinine plus 3HC were used as

alternative proxies for nicotine exposure can be found in Supplementary Tables S7-S13. The

results are generally in line with the main results with some exceptions. Increased cotinine

and cotinine plus 3HC exposure appears to increase risk of lung cancer (to a lesser extent

than non-nicotine constituents of tobacco smoke). There is also less evidence to suggest a

protective effect of nicotine on COPD among current smokers in the analyses alternatively

including cotinine and cotinine plus 3HC and there is less evidence of an effect on FEV-1 and

heart rate among current smokers in the analyses including cotinine plus 3HC.

The results among former smokers can be found in Supplementary Tables S7-S13. The

findings suggest that there are likely lasting detrimental effects of smoking, but they are

unlikely to be attributable to nicotine exposure.

Discussion

Overall, we found little evidence to suggest a major detrimental effect of nicotine exposure

on health when using an MVMR model to distinguish the direct effects of nicotine from the

direct effects of non-nicotine components of tobacco smoke (using NMR and CPD as

proxies). Our model suggests that, among current smokers, increased nicotine exposure per

cigarette smoked increases heart rate but may have protective effects on lung function and

COPD. Our findings in relation to smoking heaviness were generally as expected except for

CHD, for which there was limited evidence of an effect. In line with previous research [15-

17], increased smoking heaviness detrimentally impacted risk of lung cancer, COPD, and

CHD, as well as lung function and heart rate. As expected, and in line with evidence from a

range of human and animal studies [19], our analysis suggests that exposure to nicotine

without the remaining constituents of tobacco smoke increases heart rate (the positive

control).

In contrast to previous evidence, in which increased smoking heaviness was found to

increase risk of CHD, we found limited evidence of an effect of smoking heaviness on CHD

among ever smokers. Previous MR studies have also shown minimal evidence of this effect

using UK Biobank data [38], which could indicate that the outcome GWAS sample may not

be representative of the general population. Indeed, UK Biobank participants are more likely

to describe themselves as female, have fewer health issues, live in less socioeconomically

deprived areas, and be more highly educated, than the general population and thus the

results may suffer from "healthy volunteer" selection bias [39]. Given that CHD may

disproportionately affect men [40] and people with generally poorer health, this may

explain the limited findings. Additionally, we may have had limited power to detect this

effect given the range of causes of CHD and relatively few cases in UK Biobank.

Another unexpected finding was the apparent protective effects of nicotine on lung health

(COPD, FEV-1 and FVC) among current smokers. However, this finding may be due to those

with a lower NMR (and greater circulating nicotine per cigarette) needing to inhale less

smoke and other non-nicotine constituents per cigarette. Measuring smoking heaviness by

the number of cigarettes smoked per day will not completely capture the variation in

smoking intensity, so there could be a small effect of intensity which is captured in the

instrumental variable for NMR because increased NMR may lead to increased inhalation per

cigarette. Given the magnitude of effects found for NMR are much smaller than for smoking

heaviness, the residual variance in smoking intensity impacting the NMR estimates appears

to be limited. Furthermore, if there is a true protective effect it may not be clinically

important given the magnitude of the effects found. For example, patients only perceive

differences in FEV-1 with changes of 112 mL [41] whereas the MVMR-IVW analyses

indicated an increase of only 17.77 mL per SD increase in NMR.

In the supplementary analyses, we also saw apparent effects of cotinine and cotinine plus

3HC on lung cancer risk in the MVMR models. Given that nicotine is not thought to be

carcinogenic, these findings could indicate pleiotropic pathways are involved for these

additional exposures (e.g., via metabolism). This highlights that NMR may be a more

appropriate proxy for nicotine exposure in this context; NMR is a measure of nicotine

metabolism, therefore by including it in an MVMR model which is robust to pleiotropy via

each exposure in the model, we account for pleiotropic pathways via metabolism.

Although this is the first study to use MVMR to explore the impact of long-term nicotine

inhalation in humans and it may provide an early indication of the health impact of inhaling

nicotine via e-cigarettes, the study is not without limitations. In addition to potential issues

with "healthy volunteer" selection bias, the study is limited by the potential presence of

horizontal pleiotropy in some analyses (as indicated by effects seen in the analyses

restricted to non-smokers and the Egger analyses), which violates an assumption of the

method. The effect estimates among never smokers cannot be meaningfully interpreted as

we know that never smokers (or at least those who accurately self-report never smoking) do

not smoke any cigarettes per day despite being predisposed to heavier smoking, but

evidence of an effect in never smokers (along with a high Cochran's Q statistic) is indicative

of horizontal pleiotropy. Despite this, no effects were observed in the relationship between

NMR and the health outcomes in the MVMR analyses restricted to never smokers.

Additionally, while the MR-Egger test of directional pleiotropy indicated directional

pleiotropic effects in the relationship between smoking heaviness and health outcomes,

there was no clear evidence of directional horizontal pleiotropic effects in the relationship

between NMR and health outcomes among ever and current smokers. Therefore, these

sensitivity analyses suggest our interpretation of the direct effects of nicotine on the

selected health outcomes should not be impacted by directional horizontal pleiotropy or

population stratification.

Further limitations of the study relate to the adjustment and inclusion criteria of the GWAS

used for analysis. The first issue pertains to differences between the exposure GWAS

inclusion criteria: the GWAS of NMR was restricted to current smokers whereas the GWAS

of smoking heaviness was restricted to ever regular smokers. However, smoking heaviness

was assessed as current or past smoking heaviness (i.e., the measure is representative of

the behaviour of current smokers despite being a retrospective measure, therefore we are

assuming that the two populations are similar). If this assumption in incorrect, we may have

introduced bias into our findings. Second, in contrast to the GWAS of smoking behaviour

and the health outcomes, the NMR GWAS was adjusted for BMI. Adjusting for BMI in one

exposure variable meant that we could not clearly assess the effect of nicotine on BMI,

however it also may impact our interpretation of results where the outcomes are associated

with BMI (i.e., where BMI is a plausible co-variate of the exposure and outcome

phenotypes) [25]. As lung and heart health could be impacted by BMI [42, 43], some of the

effect sizes observed may be biased towards the null. Although there are approaches

available to correct for this bias [44], it is not feasible to implement this correction with the

limited number of SNPs included in this analysis. Therefore, we must interpret these

findings with caution. Third, we did not use data from an updated CPD GWAS with a larger

sample size and more diverse sample that was released in 2022 [45] after analysis was

complete for this study. The study team agreed that it would be detrimental to use the new

data release restricted to European ancestry. The number of SNPs found to be associated

with smoking heaviness was three times greater in the 2022 data release compared to the

2019 data release, which would cause a problematic imbalance/mismatch between the

number of SNPs used to instrument smoking heaviness versus NMR, and potentially lead to

weak instrument bias [33]. Furthermore, we were unable to use data from the multi-

ancestry GWAS of smoking heaviness [45] as the NMR GWAS did not conduct similar

analyses and was restricted to those of European descent and an assumption of MVMR is

that all data included in an MVMR model are from the same underlying population [9].

Future work could focus on the inclusion of multiple ancestries if appropriate NMR GWAS

become available to explore whether the findings generalise to non-European ancestries.

This work highlights the limited impact that long-term nicotine exposure via inhalation (e.g.,

via smoking or potentially vaping) is likely to have on heart and lung health. Given that it will

not be possible to explore the long-term effects of vaping for some years yet, and the

impact of long-term nicotine use is usually confounded by smoking, this is an important

addition to our knowledge with respect to the harms of vaping. However, there are many

more potential health outcomes (e.g., the effects on cancer progression, mental health,

sleep, perinatal outcomes etc.) which should be explored in future research. Additionally,

the effect of vaping nicotine could be impacted by nicotine absorption potentially occurring

by a different route to smoking (e.g., via oral mucosa absorption rather than lungs), or by

the difference in vehicle-delivery (i.e., via liquid droplets of propylene glycol and glycerol

rather than particulates) [46]. Furthermore, these findings cannot inform our understanding

of non-nicotine e-cigarette vapour constituent exposure; further research is therefore

needed to understand the health impact of long-term exposure to propylene glycol,

vegetable glycerine and common e-liquid flavourings. Nevertheless, the findings support the

safe long-term use of traditional pharmaceutical nicotine replacement therapies such as

nicotine patches.

Conclusions

In conclusion, the present findings indicate that long-term nicotine use (via inhalation) when

accounting for exposure to non-nicotine constituents of tobacco smoke may increase heart

rate but does not increase risk of COPD or CHD and does not appear to adversely impact

lung function. We found that, aside from effects on heart rate (which were expected given

our knowledge of effects of short-term nicotine use), there was no evidence to suggest that

long-term nicotine exposure is responsible for the detrimental effects of smoking on the

outcomes that were included in this analysis. Although further research is necessary to

explore other health outcomes and triangulate these findings, our results support existing

evidence which suggests nicotine use is not a major risk factor in the development of

smoking-related disease.

Acknowledgements

We would like to thank Rachel Tyndale and her team for their support in interpreting the

MVMR results relating to NMR and provision of summary statistics. We would also like to

thank the GSCAN and ILCCO teams (including James McKay) for the provision of summary

statistics. Quality Control filtering of the UK Biobank data was conducted by R. Mitchell, G.

Hemani, T. Dudding, L. Corbin, S. Harrison, L. Paternoster as described in the published

protocol (doi: 10.5523/bris.1ovaau5sxunp2cv8rcy88688v). The MRC IEU UK Biobank GWAS

pipeline was developed by B. Elsworth, R. Mitchell, C. Raistrick, L. Paternoster, G. Hemani, T.

Gaunt (doi: 10.5523/bris.pnoat8cxo0u52p6ynfaekeigi)**.**

Funding

JNK, RCR, MRM, ES, and AET are all members of the Medical Research Council (MRC)

Integrative Epidemiology Unit at the University of Bristol (MC_UU_00032/01,

MC_UU_00032/04, MC_UU_00032/07). REW is funded by the Norwegian South-Eastern

Regional Health Authority (2020024). This work was supported by Cancer Research UK

(grant number C18281/A29019). This work is supported by the National Institute for Health

Research (NIHR) Biomedical Research Centre at University Hospitals Bristol NHS Foundation

Trust and the University of Bristol. The views expressed in this publication are those of the

authors and not necessarily those of the NHS, the NIHR or the Department of Health and

Social Care.

References

1.   Das SK. Harmful health effects of cigarette smoking. Mol Cell Biochem. 2003;253(1-
2):159-65. Epub 2003/11/19. doi: 10.1023/a:1026024829294. PubMed PMID: 14619966.
2.   Action on Smoking and Health. Use of e-cigarettes (vapes) among adults in Great
Britain. 2022. Available from: https://ash.org.uk/uploads/Use-of-e-cigarettes-vapes-among-
adults-in-Great-Britain-2022.pdf?v=1661865959.
3.   Jackson SE, Hill E, Shahab L, Beard E, Michie S, Brown J. Prevalence and correlates of
long-term e-cigarette and nicotine replacement therapy use: a prospective study in England.
BMJ Open. 2019;9(10):e029252. Epub 2019/10/13. doi: 10.1136/bmjopen-2019-029252.
PubMed PMID: 31604784; PubMed Central PMCID: PMCPMC6797372.
4.   Shahab L, Dobbie F, Hiscock R, McNeill A, Bauld L. Prevalence and Impact of Long-
term Use of Nicotine Replacement Therapy in UK Stop-Smoking Services: Findings From the
ELONS Study. Nicotine Tob Res. 2017;20(1):81-8. Epub 2016/09/25. doi:
10.1093/ntr/ntw258. PubMed PMID: 27664995; PubMed Central PMCID: PMCPMC5896546.
5.   Lee PN, Fariss MW. A systematic review of possible serious adverse health effects of
nicotine replacement therapy. Arch Toxicol. 2017;91(4):1565-94. Epub 2016/10/05. doi:
10.1007/s00204-016-1856-y. PubMed PMID: 27699443; PubMed Central PMCID:
PMCPMC5364244.
6.   Gvozdenović E, Malvisi L, Cinconze E, Vansteelandt S, Nakanwagi P, Aris E, et al.
Causal inference concepts applied to three observational studies in the context of vaccine
development: from theory to practice. BMC Medical Research Methodology. 2021;21(1):35.
doi: 10.1186/s12874-021-01220-1.
7.   Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. Cold
Spring Harb Perspect Med. 2022;12(1). Epub 2021/08/25. doi:
10.1101/cshperspect.a040501. PubMed PMID: 34426474; PubMed Central PMCID:
PMCPMC8725623.
8.   Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR, et al.
Mendelian randomization. Nature Reviews Methods Primers. 2022;2(1):6. doi:
10.1038/s43586-021-00092-5.
9.   Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of
multivariable Mendelian randomization in the single-sample and two-sample summary data
settings. Int J Epidemiol. 2019;48(3):713-27. Epub 2018/12/12. doi: 10.1093/ije/dyy262.
PubMed PMID: 30535378; PubMed Central PMCID: PMCPMC6734942.
10.   Liu MZ, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up to
1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol
use. Nat Genet. 2019;51(2):237-+. doi: 10.1038/s41588-018-0307-5. PubMed PMID:
WOS:000457314300010.
11.   Buchwald J, Chenoweth MJ, Palviainen T, Zhu G, Benner C, Gordon S, et al. Genome-
wide association meta-analysis of nicotine metabolism and cigarette consumption measures
in smokers of European descent. Mol Psychiatry. 2020. Epub 2020/03/12. doi:
10.1038/s41380-020-0702-z. PubMed PMID: 32157176; PubMed Central PMCID:
PMCPMC7483250.
12.   Benowitz NL, Hukkanen J, Jacob P, 3rd. Nicotine chemistry, metabolism, kinetics and
biomarkers. Handb Exp Pharmacol. 2009;(192):29-60. Epub 2009/02/03. doi: 10.1007/978-
3-540-69248-5_2. PubMed PMID: 19184645; PubMed Central PMCID: PMCPMC2953858.

13.   Dempsey D, Tutka P, Jacob III P, Allen F, Schoedel K, Tyndale RF, et al. Nicotine
metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clinical
Pharmacology & Therapeutics. 2004;76(1):64-72. doi:
https://doi.org/10.1016/j.clpt.2004.02.011.
14.   Carroll DM, Murphy SE, Benowitz NL, Strasser AA, Kotlyar M, Hecht SS, et al.
Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect
Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers. Cancer
Epidemiol Biomarkers Prev. 2020;29(4):871-9. Epub 2020/02/14. doi: 10.1158/1055-
9965.Epi-19-0644. PubMed PMID: 32051195; PubMed Central PMCID: PMCPMC7437528.
15.   West R. Tobacco smoking: Health impact, prevalence, correlates and interventions.
Psychol Health. 2017;32(8):1018-36. Epub 2017/05/30. doi:
10.1080/08870446.2017.1325890. PubMed PMID: 28553727; PubMed Central PMCID:
PMCPMC5490618.
16.   Jayes L, Haslam PL, Gratziou CG, Powell P, Britton J, Vardavas C, et al. SmokeHaz:
Systematic Reviews and Meta-analyses of the Effects of Smoking on Respiratory Health.
Chest. 2016;150(1):164-79. Epub 2016/04/23. doi: 10.1016/j.chest.2016.03.060. PubMed
PMID: 27102185.
17.   Khan A, Shabbir K, Ansari JK, Zia N. Comparison of forced expiratory volume in one
second (FEV1) among asymptomatic smokers and non-smokers. J Pak Med Assoc.
2010;60(3):209-13. Epub 2010/03/17. PubMed PMID: 20225780.
18.   Hammerton G, Munafò MR. Causal inference with observational data: the need for
triangulation of evidence. Psychological Medicine. 2021;51(4):563-78. Epub 2021/03/08.
doi: 10.1017/S0033291720005127.
19.   Benowitz NL, Burbank AD. Cardiovascular toxicity of nicotine: Implications for
electronic cigarette use. Trends Cardiovasc Med. 2016;26(6):515-23. Epub 2016/04/16. doi:
10.1016/j.tcm.2016.03.001. PubMed PMID: 27079891; PubMed Central PMCID:
PMCPMC4958544.
20.   Royal College of Physicians. Nicotine without smoke: Tobacco harm reduction. .
2016.
21.   Ware JJ, Chen X, Vink J, Loukola A, Minica C, Pool R, et al. Genome-Wide Meta-
Analysis of Cotinine Levels in Cigarette Smokers Identifies Locus at 4q13.2. Sci Rep.
2016;6:20092. Epub 2016/02/03. doi: 10.1038/srep20092. PubMed PMID: 26833182;
PubMed Central PMCID: PMCPMC4735517.
22.   McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, et al. Large-scale
association analysis identifies new lung cancer susceptibility loci and heterogeneity in
genetic susceptibility across histological subtypes. Nat Genet. 2017;49(7):1126-32. Epub
2017/06/12. doi: 10.1038/ng.3892. PubMed PMID: 28604730.
23.   Elsworth B, Mitchell, R., Raistrick, C., Paternoster, L., Hemani, G., Gaunt T. MRC IEU
UK Biobank GWAS pipeline, version 2, 18/01/2019. databris. 2019. doi:
10.5523/bris.pnoat8cxo0u52p6ynfaekeigi.
24.   Mitchell R, Hemani G, Dudding T, Corbin L, Harrison S, Paternoster L. UK Biobank
Genetic Data: MRC-IEU Quality Control, version 2 - Datasets - data.bris. databris. 2018. doi:
doi:10.5523/bris.1ovaau5sxunp2cv8rcy88688v.
25.   Hartwig FP, Tilling K, Davey Smith G, Lawlor DA, Borges MC. Bias in two-sample
Mendelian randomization when using heritable covariable-adjusted summary associations.
International Journal of Epidemiology. 2021;50(5):1639-50. doi: 10.1093/ije/dyaa266.

26.   Jiang Y, Chen S, McGuire D, Chen F, Liu M, Iacono WG, et al. Proper conditional
analysis in the presence of missing data: Application to large scale meta-analysis of tobacco
use phenotypes. PLOS Genetics. 2018;14(7):e1007452. doi: 10.1371/journal.pgen.1007452.
27.   Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex
trait analysis. Am J Hum Genet. 2011;88(1):76-82. Epub 2010/12/17. doi:
10.1016/j.ajhg.2010.11.011. PubMed PMID: 21167468.
28.   Allen NE, Sudlow C, Peakman T, Collins R, Biobank UK. UK biobank data: come and
get it. Sci Transl Med. 2014;6(224):224ed4. Epub 2014/02/21. doi:
10.1126/scitranslmed.3008601. PubMed PMID: 24553384.
29.   Mitchell R, Hemani G, Dudding T, Corbin L, Harrison S, Paternoster L. UK Biobank
Genetic Data: MRC-IEU Quality Control, version 2. 2019. doi:
https://doi.org/10.5523/bris.1ovaau5sxunp2cv8rcy88688v.
30.   Loh PR, Tucker G, Bulik-Sullivan BK, Vilhjalmsson BJ, Finucane HK, Salem RM, et al.
Efficient Bayesian mixed-model analysis increases association power in large cohorts. Nat
Genet. 2015;47(3):284-90. Epub 2015/02/03. doi: 10.1038/ng.3190. PubMed PMID:
25642633; PubMed Central PMCID: PMCPMC4342297.
31.   Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for
biobank-scale datasets. Nat Genet. 2018;50(7):906-8. doi: 10.1038/s41588-018-0144-6.
PubMed PMID: WOS:000437224400002.
32.   Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic
instruments in two-sample multivariable Mendelian randomization. Stat Med.
2021;40(25):5434-52. Epub 2021/08/03. doi: 10.1002/sim.9133. PubMed PMID: 34338327;
PubMed Central PMCID: PMCPMC9479726.
33.   Sanderson E, Spiller W, Bowden J. Testing and Correcting for Weak and Pleiotropic
Instruments in Two-Sample Multivariable Mendelian Randomisation. bioRxiv.
2020:2020.04.02.021980. doi: 10.1101/2020.04.02.021980.
34.   Bowden J, Del Greco M F, Minelli C, Zhao Q, Lawlor DA, Sheehan NA, et al. Improving
the accuracy of two-sample summary-data Mendelian randomization: moving beyond the
NOME assumption. International Journal of Epidemiology. 2018;48(3):728-42. doi:
10.1093/ije/dyy258.
35.   Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian
randomization: Using genes as instruments for making causal inferences in epidemiology.
Statistics in Medicine. 2008;27(8):1133-63. doi: https://doi.org/10.1002/sim.3034.
36.   Rees JMB, Wood AM, Burgess S. Extending the MR-Egger method for multivariable
Mendelian randomization to correct for both measured and unmeasured pleiotropy.
Statistics in Medicine. 2017;36(29):4705-18. doi: 10.1002/sim.7492.
37.   Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele
TJ, et al. Strengthening the reporting of observational studies in epidemiology using
mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ.
2021;375:n2233. doi: 10.1136/bmj.n2233.
38.   King C, Mulugeta A, Nabi F, Walton R, Zhou A, Hyppönen E. Mendelian
randomization case-control PheWAS in UK Biobank shows evidence of causality for smoking
intensity in 28 distinct clinical conditions. EClinicalMedicine. 2020;26:100488. Epub
2020/10/23. doi: 10.1016/j.eclinm.2020.100488. PubMed PMID: 33089118; PubMed Central
PMCID: PMCPMC7564324.
39.   Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison
of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With

Those of the General Population. American Journal of Epidemiology. 2017;186(9):1026-34.
doi: 10.1093/aje/kwx246.
40. Bots SH, Peters SAE, Woodward M. Sex differences in coronary heart disease and
stroke mortality: a global assessment of the effect of ageing between 1980 and 2010. BMJ
Global Health. 2017;2(2):e000298. doi: 10.1136/bmjgh-2017-000298.
41. Donohue JF. Minimal Clinically Important Differences in COPD Lung Function. COPD:
Journal of Chronic Obstructive Pulmonary Disease. 2005;2(1):111-24. doi: 10.1081/COPD-
200053377.
42. Hypponen E, Mulugeta A, Zhou A, Santhanakrishnan VK. A data-driven approach for
studying the role of body mass in multiple diseases: a phenome-wide registry-based case-
control study in the UK Biobank. Lancet Digit Health. 2019;1(3):e116-e26. Epub 2019/07/01.
doi: 10.1016/S2589-7500(19)30028-7. PubMed PMID: 33323262.
43. Peralta GP, Marcon A, Carsin A-E, Abramson MJ, Accordini S, Amaral AF, et al. Body
mass index and weight change are associated with adult lung function trajectories: the
prospective ECRHS study. Thorax. 2020;75(4):313-20. doi: 10.1136/thoraxjnl-2019-213880.
44. Gilbody J, Borges MC, Smith GD, Sanderson E. Multivariable MR can mitigate bias in
two-sample MR using covariable-adjusted summary associations. medRxiv.
2022:2022.07.19.22277803. doi: 10.1101/2022.07.19.22277803.
45. Saunders GRB, Wang X, Chen F, Jang S-K, Liu M, Wang C, et al. Genetic diversity fuels
gene discovery for tobacco and alcohol use. Nature. 2022;612(7941):720-4. doi:
10.1038/s41586-022-05477-4.
46. Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, Romagna G, Voudris V.
Nicotine absorption from electronic cigarette use: comparison between first and new-
generation devices. Sci Rep. 2014;4:4133. Epub 2014/02/27. doi: 10.1038/srep04133.
PubMed PMID: 24569565; PubMed Central PMCID: PMCPMC3935206.
822